NCT07416786 Validation of NAD+ Measurements for Human Clinical Studies
| NCT ID | NCT07416786 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Healthy Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2026-09-01 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).
Eligibility Criteria
* Male or female age18-35 years or 70 years or older, healthy * if female reproductive potential, use of highly effective contraception (at least 1 month prior to screening and during study participation). * No known sensitivity to NR * No use of niacin, blood thinners or chemotherapy agents * HbA1c below 8.5% and not diabetec requiring insulin. * Not using/taking corticosteroids * No laboratory abnormalities indicating significant anemia, bleeding risk, kidney disease, or liver disease * No contraindication to MRI * Not Pregnant, lactating, or planning to become pregnant during participation * Not taking multivitamins or any over-the-counter supplements except calcium and vitamin D (any other supplements - discontinued 2 weeks prior to study participation). * not taking/ undergoing another investigational drug or other intervention within the past 30 days.
Contact & Investigator
Ravinder Reddy, Ph.D.
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT07416786 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Healthy Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07416786 currently recruiting?
Yes, NCT07416786 is actively recruiting participants. Contact the research team at cdamodar@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07416786 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07416786 clinical trial?
NCT07416786 is sponsored by University of Pennsylvania. The principal investigator is Ravinder Reddy, Ph.D. at University of Pennsylvania. The trial plans to enroll 48 participants.